Immunotherapy Gene Therapy Targeted Therapies Cell Therapy Gene Editing Electromagnetic Therapy T-cell Engagers CAR T Cell Therapy Flu Prevention Antibody-Drug Conjugates Radioactive Treatment CFTR Modulators Biocompatibility Neuroscience Alpha-Emitting Therapies Oxygen Treatments Regenerative Medicine Drug Development Music Therapy Long-Acting Biologics Combination Therapies Biotechnology Cellular Therapy Combination Treatments Non-invasive Techniques Viral Therapy siRNA Therapy CAR-NK Therapy Genetic Engineering RNA Interference CAR-T Therapy Ultrasound Technology KRAS Inhibitors Living Medicines Drug Delivery Systems iPSC-derived Therapies Universal CAR-T Therapy Research Institutions Cytokines Radiation Therapy CAR T-cell Therapy
The agreement gives Lilly exclusive development and commercial control outside Korea, with Hanmi taking a $75 million up‑front payment and large milestone and royalty upside.
